Synaptogenix Price to Free Cash Flow Ratio 2020-2025 | TAOX
Historical price to free cash flow ratio values for Synaptogenix (TAOX) since 2020.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Synaptogenix Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-07-02 |
8.08 |
|
0.00 |
| 2025-03-31 |
2.42 |
$-3.63 |
0.00 |
| 2024-12-31 |
3.47 |
$-3.96 |
0.00 |
| 2024-09-30 |
3.02 |
$-4.32 |
0.00 |
| 2024-06-30 |
4.10 |
$-3.37 |
0.00 |
| 2024-03-31 |
4.69 |
$-7.21 |
0.00 |
| 2023-12-31 |
6.80 |
$-11.11 |
0.00 |
| 2023-09-30 |
11.00 |
$-19.56 |
0.00 |
| 2023-06-30 |
23.19 |
$-28.49 |
0.00 |
| 2023-03-31 |
20.00 |
$-33.23 |
0.00 |
| 2022-12-31 |
29.00 |
$-40.13 |
0.00 |
| 2022-09-30 |
167.50 |
$-46.72 |
0.00 |
| 2022-06-30 |
129.75 |
$-29.87 |
0.00 |
| 2022-03-31 |
193.50 |
$-25.79 |
0.00 |
| 2021-12-31 |
212.75 |
$-43.44 |
0.00 |
| 2021-09-30 |
248.50 |
$-26.89 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.011B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
